Company history and financing
Vigeo Therapeutics, based in Cambridge, MA, is a clinical-stage biopharmaceutical company developing novel therapeutics that have the potential to treat multiple types of cancer and improve the lives of patients. Vigeo was co-founded by Randolph Watnick, Ph.D., a pioneer in understanding the role of the tumor microenvironment in metastasis, and Jing Watnick, Ph.D., M.B.A., an accomplished research scientist and leader in biopharmaceutical development.
To provide financing for the development of its science and its organization, Vigeo has partnered with Morningside Venture Investments, Ltd, a private equity and venture capital firm founded in 1992. Vigeo has secured Series A and B rounds of financing in 2015 and 2018, respectively.